Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$1.3 billion.

  • Takeda Pharmaceutical's Cash from Financing Activities rose 7102.32% to -$1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.8 billion, marking a year-over-year decrease of 4048.83%. This contributed to the annual value of -$4.9 billion for FY2025, which is 10072.69% down from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Cash from Financing Activities is -$1.3 billion, which was up 7102.32% from -$81.3 million recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Cash from Financing Activities peaked at $2.0 billion during Q2 2024, and registered a low of -$4.3 billion during Q4 2024.
  • In the last 5 years, Takeda Pharmaceutical's Cash from Financing Activities had a median value of -$1.4 billion in 2021 and averaged -$1.4 billion.
  • Over the last 5 years, Takeda Pharmaceutical's Cash from Financing Activities had its largest YoY gain of 58206.65% in 2024, and its largest YoY loss of 68739.72% in 2024.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Cash from Financing Activities stood at -$1.5 billion in 2021, then plummeted by 108.24% to -$3.1 billion in 2022, then surged by 78.52% to -$661.4 million in 2023, then plummeted by 552.41% to -$4.3 billion in 2024, then surged by 71.02% to -$1.3 billion in 2025.
  • Its Cash from Financing Activities stands at -$1.3 billion for Q4 2025, versus -$81.3 million for Q3 2025 and -$1.5 billion for Q2 2025.